Green Thumb Industries (GTII.CN) closed at 8.6 CAD on October 16, 2026, down 5.0% on the day and 25.2% below its September 23 peak of 11.5 CAD. The balance of evidence for the next 2–6 weeks leans negative, with high conviction (3 of 4 points). The daily trend runs with the weekly downtrend, and the shares trail both the S&P 500 and the healthcare sector. No news explains the slide.
Why it matters
The only dated item in the file is sector news from September 2, 2026, and it is not about GTII.CN. Curaleaf PR Newswire responded to Aurora Cannabis's rejection of its offer, defending a 45% premium bid and saying Aurora has raised $398 million through dilutive equity since September 2020. That is a fight over how a cannabis company should be valued. It says little about why GTII.CN fell from 11.5 CAD in late September to 8.6 CAD, and the news does not account for that move.
What the price shows is a stock that was not already holding up. It has lost 17.1% in a month and 22.0% year to date, while the S&P 500 is up 11.8% for the year and XLV up 14.2%. The last week widened the gap. The shares fell 7.7% over five days while the S&P 500 lost 2.1% and XLV gained 3.5%. That leaves the stock 11.2 points behind its sector over the week, so most of the damage is specific to GTII.CN rather than the market or healthcare. Over 50 days the shares lag the S&P 500 by 14.7% and XLV by 18.5%. When a stock falls against a rising sector without company news, the usual cause is holders reducing positions, and that tends to continue until buyers show up at a visible level.
There is no live debate to weigh. No articles arguing a case for or against GTII.CN were available, and the file has no analyst count, consensus or price target. The nearest thing to an argument is the Curaleaf and Aurora dispute. One side holds that a premium bid shows what sector assets can fetch. The other holds that diluted balance sheets deserve skepticism. Neither side is about GTII.CN, so valuation cannot be set against an analyst spread. With a market value near 1.9 billion CAD and shares 35.2% below their 52-week high of 13.27 CAD, the market is clearly pricing in a lot of doubt, but the file gives no outside anchor for how much.
What the evidence says
The long-term picture is weakened and sliding toward broken. Price is below both its 10-week and 40-week averages, which puts the stock in a downtrend. It has also fallen well below the 50-day average at 10.14 CAD and the 200-day at 10.07 CAD, two lines that sit almost on top of each other. That is a stock in a markdown phase after failing near 11.5 CAD, not one basing. The 52-week low of 7.4 CAD is the next structural floor, and the price is 16.2% above it.
For the next 2–6 weeks the balance of evidence leans negative, and conviction is high at 3 of 4 points. The daily trend agrees with the weekly downtrend, which is the cleanest form of the signal. Relative strength is poor against both the market and the sector, so the weakness is not a general one that a market rebound would cure. The previous note on October 16, 2026 reached the same conclusion with the same level for the trend to end, 9.92 CAD. Nothing since has pushed the price toward that level. The weekly close above it has not come, and the shares have moved further from it.
The strongest case against this reading is the speed of the fall. The 14-day RSI is 21.7, deeply oversold, and the stock has dropped 25.2% in under a month. Oversold stocks in downtrends often bounce hard, and a move back to 9.0 CAD, where sellers have shown up before, would be a normal relief rally. XLV rising 3.5% in a week also shows money is available in the sector. That is why the evidence stops short of the fourth point. It does not tip the balance, because a bounce to 9.0 CAD would still sit below the 9.92 CAD level that ends the downtrend, and a bounce inside a downtrend is what this kind of oversold reading usually produces.
Levels that matter
The structure holds below 9.0 CAD, a swing zone where sellers have appeared on earlier rallies. The weekly downtrend ends only above 9.92 CAD, another swing zone. Above that sit the round 10 CAD and the 200-day and 50-day averages at 10.07 CAD and 10.14 CAD, so a recovery would meet a stack of resistance rather than a single line. Support starts at the round 8.0 CAD, then the 52-week low at 7.4 CAD, then 7.0 CAD.
The downside breakout level is a daily close below 8.0 CAD. From there the one target on the map is the 52-week low at 7.4 CAD. A move that fails would be one that recovers to 9.11 CAD, which is the 9.0 CAD swing zone plus a quarter of the 0.44 CAD average daily range. The reward-to-risk comes to 0.5 to 1, so the math does not reach the 3 to 1 that makes a breakout worth the risk. A 3 to 1 reading would need a target well beyond the 52-week low, or a much tighter stop. Neither exists on the current map, and a close below 8.0 CAD would mostly say the downtrend is continuing rather than offer favorable math.
What would change the picture
A weekly close above 9.92 CAD would change the picture. That is the first level at which the weekly downtrend would be in question, and it would mean buyers had absorbed the sellers who have capped every rally. The non-price fact that would do it is an earnings report on November 4, 2026 that gives a company-specific reason for the selling to stop, since the news file offers none today. Without such a fact, a move into 9.0 CAD is a rally inside the downtrend.
What to watch
- Earnings on November 4, 2026: the number that matters is whether sales and margins hold up, since the market has been selling the stock without a stated reason.
- The sector before the company: the Curaleaf and Aurora contest and any further cannabis consolidation news can move GTII.CN before its own results, as can XLV, which has been rising while the shares fell.
- Levels: a daily close below 8.0 CAD on the downside, a weekly close above 9.92 CAD on the upside.
- Valuation: no analyst consensus or price target is available, so there is no outside spread to measure the shares against. The 52-week range of 7.4 CAD to 13.27 CAD is the only valuation frame in the data.